| Literature DB >> 14761253 |
Melvin R Hayden1, Suresh C Tyagi.
Abstract
BACKGROUND: Vascularization is an exciting and complex mechanism involving angiogenesis and arteriogenesis. The metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM) are associated with multiple metabolic toxicities, which result in reactive oxygen species (ROS) due to an elevated tension of oxidative-redox stress and an accelerated atherosclerosis termed atheroscleropathy.Entities:
Year: 2004 PMID: 14761253 PMCID: PMC356925 DOI: 10.1186/1475-2840-3-1
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Figure 1The important role of the metabolic syndrome in the development of coronary heart disease. The metabolic syndrome consists of multiple clinical syndromes and metabolic abnormalities, which accelerates the atherosclerotic process. The NCEP ATP III guidelines allows for an easier identifications of these patients at risk. While insulin resistance is central to the development of coronary heart disease, it can be seen that each of the components now contained within the metabolic syndrome can individually contribute to CHD risk. Each of these factors is combined as in the metabolic syndrome they become synergistic.
Figure 2The atheroscleropathy associated with MS, PD, and T2DM has many deleterious pathways. There are multiple deleterious pathways associated with MS, PD, and T2DM. Atheroscleropathy is pro oxidative-redox stress, prothrombotic, pro-fibrotic, and pro-inflammatory. Each of these mechanisms and the disease process of atheroscleropathy promote a pro-angiogenic environment and associated with a diabetic vascularization paradox, in that, plaque angiogenesis is induced and arteriogenesis is impaired.
The role of angiogenesis in the classification of arterial lesions compared to tumors: benign verses malignant
| Lesion remains less 3–4 mm if no angiogenesis | |
Figure 3Vulnerability of the thin cap fibroatheroma. The vulnerable plaque: Currently the vulnerable plaque has been defined as containing the following: 1. Large lipid core. 2. Thin fibrous cap. 3. Inflammatory changes at the shoulder of the fibrous cap. 4. Decreased smooth muscle cells within the fibrous cap. This "Hot" – vulnerable thin-cap fibrous atheromatous plaque is associated with angiogenesis, inflammation, being lipid laden and acidic, and fibrotic. The endothelium is activated and these plaques are prone to rupture resulting in acute coronary syndromes.
Figure 4Plaque angiogenesis induced in MS, PD, and T2DM. Angiogenesis within the unstable atherosclerotic plaque: In health the vasa vasorum usually has a single vessel that runs parallel to each side of the epicardial artery being nourished with occasional interconnecting conduits from one side of the artery to the other. In this image, the native parallel adventitial vasa vasorum (in black) can be differentiated from the red neovascularization of the intima and media. The unstable, vulnerable plaques are associated with a malignant like invasion of the intima-media by adventitial derived vasa vasorum fragile vessels, which are prone to rupture resulting in intraplaque hemorrhage. These intraplaque hemorrhages accelerate plaque vulnerability and are associated with plaque rupture and acute coronary events.
The 10-point process of Angiogenesis:
| 1. Endothelial cell activation and Proliferation. |
| 2. Local Vasodilatation. |
| 3. Increased vascular permeability. |
| 4. Accumulation of extravascular fibrin* PAI-1 |
| 5. |
| 6. Thin cytoplasmic processes are extended from the endothelial cell. |
| 7. Directed migration into surrounding ECM toward the Angiogenic Stimulus (IPH or Ischemia). |
| 8. E. Cells. elongate and align to form a capillary Sprout. |
| 9. E. Cell. Division proximal to the migrating tip. |
| 10. Reconstitution of the basement membrane. |
| • |
| • |
| • |
| • |
Figure 5The 10 point process of angiogenesis visulized. The 10 point process of angiogenesis: Intraplaque hemorrhage (IPH) may serve as an angiogenic stimulus for the further development of excessive vasa vasorum invasion of the intima and media, resulting in an even more unstable vulnerable plaque: prone to rupture. As the MMPs drill the openings for the invading adventitial Vv they may also contribute to the disruption of the internal elastic lamina, which contributes to the plaques instability. Additionally, the extravasated RBC plasma membranes become incorporated into the necrotic core and contribute to the enlargement of the necrotic core, as well as, providing an antigenic stimulus for the continued intraplaque inflammatory response.
Figure 6The This figure compares and contrasts the involved mechanisms of angiogenesis and arteriogenesis. S = substrates, P = promotors, I = inducers, R = results, I = the common role of inflammation, and T = time. This acronym helps to understand why angiogenesis is induced and arteriogenesis is impaired.
Figure 7Impairment of remodeling collateralization due to PAI-1. PAI-1 elevations impair fibrinolysis and contribute to a prothrombotic state in MS, PD, and T2DM. Additionally PAI-1 elevations impair Arteriogenesis. Remodeling collateralization is impaired in MS, PD, and T2DM due to elevations in PAI-1. Conversion of plasminogen to plasmin by tPA – uPA is negatively effected by elevations in PAI-1. This defect in the generation of Plasmin results in decreased conversion of latent MMPs to active MMPs and impair the remodeling necessary for the required remodeling of the preexisting arterioles to larger arterioles necessary for a more functional blood flow around obstructed epicardial coronary arteries and obstructed peripheral vascular systems in MS, PD, and T2DM.
THE SPIRIT OF VASCULARIZATION (SEE FIGURE 6)
| Capillary | Arterioles | |
| Hif-1 | Shear Stress | |
| Ischemia | Shear Stress | |
| More Capillaries | Larger remodeled Arteriole | |
| Hours → Days | Days → Weeks → Months | |
| NORMOXIA |
Multiple metabolic toxicities in ms and t2dm: the a-flight acronym
| Hyperamylinemia | Activation of ANG II | PKC Signal Transduction | ROS | ||
| Ang II Excess | Ang II Excess | PKC Signal Transduction. Superoxide production. Uncoupling of the eNOS reaction. TGF beta-1 activation | ROS NAD(P)H oxidase Derived Superoxide | ||
| AGE / AFE See Glucotoxicity (G) | Protein Cross – linking / Dysfunction | Matrix Defects Signal Transduction | ROS Myocardial, Renal, Intimal, Retinal, Neuronal– Endoneurial Fibrosis | ||
| ALE | Protein Cross – linking | Matrix Defects Signal Transduction | ROS Matrix Remodeling | ||
| Reduced – Dysfunctional eNOS, SOD, GPx, GSH, Catalase, and Vit. C. | Decreased NO | Decreased NO REDOX STRESS | ROS REDOX STRESS | ||
| IMPAIRED eNOS L-arginine BH4 | Decreased NO | Decreased NO | ROS Decreased NO | ||
| Increased Ox-LDL-C, TNFalpha, Capase 3, Glomerulosclerosis. | Decreased NO: | Decreased NO | ROS Inflammation, Apoptosis | ||
| ROS beget ROS | Decreased NO Athero – emboli Activated Platelets See Thrombotic Tox. | ROS beget ROS Decreased NO | |||
| Elevated FFA | LC acyl -CoA's | Mitochondrial Defects | ROS Cytotoxicity | ||
| Increased VLDL – VLDL Triglycerides and Small dense atherogenic LDL-Cholesterol with Decreased HDL-Cholesterol LIPID TRIAD | LC acyl -CoA's Fat Accumulation | Non Adipose Accumulation of Fat (LC acyl -CoA's) in Adipose and Non Adipose Tissue | ROS Accumulation of fat in non adipose tissues resulting in Ceramide induced: Cytotoxicity | ||
| Hyperinsulinemia | Ang II | NAD(P)H | ROS | ||
| Inflammation toxicity. "Inflammatory Cycle" | Activation of the innate immune system: IL-6, IL-8, TNF alpha | Acute Phase Reactants: C-Reactive Protein Serum Amyloid A Fibrinogen | NF kappa B Cellular Adhesion Molecules: ICAM, VCAM, and MCP-1 | ROS Inflammation begets Inflammation " INFLAMMATORY CYCLE " ROS beget ROS | |
| Glycation / AGE | See above | See above | See above | ||
| Protein inactivation | Receptor-ligand defects | Dysfunctional Signal Transduction | |||
| NO quenching | Vasoconstriction | Ischemia/Hypoxia ROS | |||
| Macrophage Activation | Increased Cytokines, TGF-Beta | Cytotoxicity ROS | |||
| Free Radical Formation | REDOX STRESS | Cytotoxicity ROS | |||
| Auto-oxidation | Free Radical Formation | REDOX STRESS | Cytotoxicity ROS | ||
| ORIGIN OF REDUCTIVE STRESS ! REDUCTIVE STRESS ! | Polyol Sorbitol Pathway (eNO inhibits Aldose Reductase) | Increased NADH Lactate REDUCTIVE STRESS | REDOX STRESS Decreased NO Pseudohypoxia | Cytotoxicity ROS Ischemia/ Hypoxia | |
| Decreased Taurine | REDOX STRESS | ROS Cytotoxicity | |||
| Increased DAG | Increased PKC | Signal Transduction REDOX STRESS | Ischemia ROS | ||
| Polyol – Sorbitol Pathway | PAS + material Interstitium, Basement Membrane | Remodeling – CHF Diastolic Dysfunction | |||
| Hypertension Toxicity | RAAS activation Hyperhomocysteinemia NO quenching and NEW: PPAR interaction. | Ang II Decreased GPx, DDAH with resultant ^ ADMA | NAD(P)H REDOX STRESS ^ ROS, O2', ONOO', nitrotyrosine | ROS Decreased NO, Endothelial Cell toxicity, dysfunction, and apoptosis | |
| Triglyceride Toxicity Thrombotic Toxicity Taurine (antioxidant) depletion | Triglyceride – FFA exchange | See FFA – Lipotoxicity above eNOS uncoupling | REDOX STRESS Activated Platelets PAI-1 elevation Fibrinogen elevated. Decreased NO | ROS Athero-emboli ROS |
THE RAAS ACRONYM: GLOBAL RISK REDUCTION
In order of appearance.
| Angiotensin II. | |
| Renin angiotensin aldosterone system. | |
| Reactive Oxygen Species ( | |
| Angiotensin type one receptor. | |
| Protein Kinase C. | |
| Islet Amyloid Polypeptide. | |
| Transforming Growth Factor beta-1. | |
| Nicotine Adenine Di nucleotide Phosphate reduced oxidase. | |
| Advanced Glycation Endproducts. | |
| Advanced Fructosylation Endproducts. | |
| Receptor for Advanced Glycosylation Endproducts. | |
| Advanced Lipoxidation Endproducts. | |
| Endothelial Nitric Oxide Synthase. | |
| Nitric Oxide. | |
| Tetra Hydro Biopterin. | |
| Free Fatty Acids. | |
| Long chain Acyl Co enzyme CoA. | |
| Very low density lipoprotein. | |
| Low density lipoprotein. | |
| High density lipoprotein. | |
| Metabolic Syndrome. | |
| Prediabetes. | |
| Type 2 Diabetes Mellitus. | |
| Plasminogen Activator Inhibitor-1. | |
| Water. | |
| Glucose Transporter-4. | |
| Phosotidyl inositol 3 Kinase. | |
| Protein kinase B. | |
| Mitogen Activated Protein Kinase. | |
| ___ | |
| Interleukin-6 Interleukin-8. | |
| Tumor Necrosis Factor alpha. | |
| Myeloperoxidase: Generation of Superoxide ( | |
| Nuclear Factor kappa B. | |
| Inter Cellular Adhesion Molecule. | |
| Vascular Cellular Adhesion Molecule. | |
| Monocyte Chemoattractant Protein-1 | |
| Nicotinamide Adenine Dinucleotide reduced | |
| Nicotinamide Adenine Dinucleotide oxidized | |
| Diacylglycerol. | |
| Glutathione Peroxidase. | |
| Asymmetrical dimethyl arginine. | |
| Superoxide – Peroxynitrite. |